BPC-157

Background and origin

BPC-157 is a synthetic pentadecapeptide (15 amino acids; sequence: GEPPPGKPADDAGLV) with a molecular weight of approximately 1,419 daltons. The name derives from "body protection compound," a description applied by the Zagreb research group that isolated a partial sequence from proteins found in human gastric juice. The isolated sequence was then synthesized chemically and studied in animal models. BPC-157 does not occur naturally at the concentrations or in the form used in experiments; it is an entirely synthetic research compound.

The peptide is stable in gastric acid in vitro, which is one reason early studies explored oral and intragastric routes in rodent models alongside subcutaneous and intraperitoneal administration. Whether gastric stability translates to meaningful oral bioavailability in humans has not been studied; the assumption of oral activity in humans is speculative.^[1]

Research on BPC-157 has been conducted primarily by Predrag Sikiric and colleagues at the University of Zagreb School of Medicine. The volume of published preclinical work is substantial, but concentration of the primary literature in a single research group is a recognized limitation when evaluating reproducibility and generalizability.

Proposed mechanisms (preclinical)

In rodent and cell-culture models, BPC-157 has been proposed to act through several pathways. These are proposals based on preclinical observations, not confirmed human pharmacology:

• Nitric oxide (NO) system modulation: Several rodent studies have reported changes in NO synthesis following BPC-157 administration. The direction and magnitude of the effect appear to vary with model and dose, and the underlying mechanism is not fully characterized even at the preclinical level.^[1]
• Angiogenesis via VEGFR2 upregulation: Preclinical data suggest BPC-157 may increase expression of vascular endothelial growth factor receptor 2 (VEGFR2), potentially promoting new blood vessel formation in injured tissue. This has been proposed as a mechanism underlying wound and tendon healing observations in rodents.^[5]
• Growth factor expression: Rodent studies have reported increases in expression of fibroblast growth factor (FGF) and epidermal growth factor (EGF) in treated tissue. Whether these changes are direct or secondary to other effects is not established.
• Tendon fibroblast outgrowth: In-vitro and in-vivo rodent data have shown enhanced outgrowth and migration of tendon fibroblasts in the presence of BPC-157, which has been proposed to underlie the musculoskeletal healing effects seen in animal models.^[3]
• Dopaminergic and serotonergic system interaction: A subset of published studies from the Zagreb group has examined BPC-157 in rodent models of dopamine and serotonin dysregulation. These findings are preliminary, and the behavioral and neurochemical observations in rodents do not translate directly to clinical psychiatric indications.

A fuller discussion of each proposed pathway and its evidentiary basis is in: BPC-157 proposed mechanisms of action

Preclinical therapeutic areas studied

Rodent studies have examined BPC-157 across a range of injury and disease models. The following areas have received the most attention in published literature; in each case the evidence is exclusively or almost entirely preclinical:

No completed, peer-reviewed randomized controlled trial in humans has been published for any of these indications as of the last review date.

Pharmacokinetics: what is not known

No peer-reviewed human pharmacokinetic study for BPC-157 has been published. Key unknowns include:

• Half-life in humans: Some preclinical papers report a very short intravenous half-life in rats (estimated on the order of minutes to roughly 30 minutes), but species differences in peptide metabolism and assay variability make this figure unreliable as a human estimate.
• Oral bioavailability: Though the peptide is stable in gastric acid, stability in acid does not guarantee intestinal absorption. Oral bioavailability in humans is entirely unstudied.
• Distribution, tissue penetration, and protein binding: No human data exist.
• Metabolic pathways in humans: The peptide would be expected to undergo proteolytic degradation, but the specific enzymes, metabolites, and elimination routes in humans are not characterized.

A detailed treatment of the pharmacokinetic evidence and its limitations is in: BPC-157 half-life and pharmacokinetics

Safety: the scope of the unknown

Human safety data for BPC-157 do not exist in peer-reviewed form. Rodent acute toxicity studies have reported a wide apparent therapeutic window (high doses in animals did not produce overt toxic effects in the studies reported), but this cannot be extrapolated to humans. Specific unknowns include immunogenicity, off-target receptor interactions at human-relevant concentrations, long-term organ effects, interactions with medications, and effects in vulnerable populations such as people with renal or hepatic disease, pregnant or breastfeeding individuals, or children.

Because BPC-157 has not entered formal Phase I clinical evaluation, no human pharmacovigilance data exist. Adverse event reports from individuals who have self-administered the compound are not systematically collected or reviewed by any regulatory body.

The safety article covers this topic in more detail: BPC-157 safety profile

Regulatory status

BPC-157 is not approved as a medicine, supplement, or therapeutic in any of the five jurisdictions covered by this hub (US, EU, UK, AU, CA) or, to our knowledge, in any other major regulatory framework. It is sold by several international vendors as a research chemical for laboratory use; most product listings include disclaimers stating the compound is not intended for human use.

In the United States, the FDA has not approved any drug application for BPC-157 and there are no IND applications on the public record. In the European Union, no centralised or national marketing authorisation exists. The United Kingdom, Australia, and Canada have likewise made no regulatory determinations on the compound as a medicine.

Use the region switcher to view the agency-specific regulatory note for each jurisdiction. The status shown in all regions is "research-only" or "not approved," which accurately reflects the absence of any approved therapeutic indication.